Hims & Hers Health Inc. soared after Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth platforms. The strategy comes as rival ...
Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...
Hosted on MSN
Where Is Hims & Hers Stock Headed After Wegovy Tie-Up? Retail Traders Bet On Rebound To Over 2-Month High
Shares of Hims & Hers Health, Inc. (HIMS) marked their best session in nearly three months on Tuesday, surging over 23% after the telehealth firm expanded its offerings to include a pharmaceutical ...
Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million users fueling growth. Despite the Novo Nordisk partnership loss, Hims ...
Virtual healthcare is rapidly evolving, led by Hims & Hers Health, Inc. HIMS and Teladoc Health, Inc. TDOC. HIMS offers a consumer-centric, subscription-based platform providing access to personalized ...
The move will rapidly expand Hims & Hers’ reach, which has a current base of 2.4 million U.S. customers. As the only digital health company with over a decade of operations across Germany, France, ...
Hims & Hers Health, Inc. (NYSE:HIMS) on Tuesday agreed to acquire ZAVA, a European digital health platform. The deal terms were not disclosed. The acquisition consideration will be 100% cash, funded ...
Tuesday, online health and wellness company Hims & Hers announced its intent to acquire European digital healthcare provider Zava in an all-cash deal. It’s part of a broader effort for the telehealth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback